Auro Pharma completes Apotex acquisition in 5 countries

Aurobindo Pharma, the Hyderabad-based pharmaceutical company, has completed the acquisition of Apotex’s commercial operations and certain supporting infrastructure in five European countries Poland, Czech Republic, the Netherlands, Spain and Belgium.

The acquisition also includes the infrastructure, personnel products, certain trademarks, marketing authorizations and dossier license rights in these five countries.

The company has recently reported Q3FY19 numbers with rise in revenue by 21.5 per cent on YoY basis. Its EU formulation segment has posted 10.3 per cent YoY growth in terms of revenue.

Also, the company has launched seven products (including two injectables) during the quarter. Further, it filed 10 new abbreviated new drug applications (ANDAs) with the USFDA, including four for injectable products during Q3FY19.

On Monday, the stock of Aurobindo Pharma opened at Rs. 764 per share and made an intraday high and low of Rs. 770.35 and Rs. 756.65 on the BSE. At 10:06 hours, the stock was trading nearly at Rs. 760.35. The stock had hit its 52-week high of Rs. 830 on December 4, 2018 and its 52-week low of Rs. 527.05 on June 4, 2018 on the BSE.